Humoral responses to hivconsv induced by heterologous vaccine modalities in rhesus macaques

Nicola J. Borthwick, Maxim Rosario, Torben Schiffner, Emma Bowles, Tina Ahmed, Peter Liljeström, Guillaume E. Stewart-Jones, Jan W. Drijfhout, Cornelis J.M. Melief, Tomas Hanke

Research output: Contribution to journalArticle

Abstract

Vaccines delivering T cell immunogen HIVconsv vectored by plasmid DNA, non-replicating simian adenovirus and non-replicating modified vaccinia virus Ankara (MVA) are under clinical evaluation in phase I/IIa trials in UK, Europe, and Africa. While these vaccines aim to induce effector T cell responses specific for HIV-1, we here characterized the humoral responses induced by HIVconsv administration to macaques using six different vaccine modalities: plasmid DNA, human adenovirus serotype 5, simian adenovirus serotype 63, MVA, Semliki Forest virus replicons, and adjuvanted overlapping synthetic long peptides (SLP). We found that only the SLP formulation, but none of the genetic vaccine platforms induced antibodies recognizing linear HIVconsv epitopes, median 32/46 SLP.HIVconsv peptides. These antibodies bound to 15-mer and SLP peptides, recombinant gp120 and trimeric gp140 of HIV-1 Bal, YU2, JRFL, and UG037, but failed to react with HIV-1 Bal and IIIB virions and HIV-1 Bal-and IIIB-infected human cells, and consequently failed to induce neutralizing antibodies. The HIVconsv immunogen contains conserved regions derived from Gag, Pol, Vif, and Env proteins of HIV-1, and antibodies induced by the SLP.HIVconsv vaccination resulted in positive signals in routine HIV-1 tests. Thus, only HIVconsv delivered by SLP resulted in seroconversion, an observation that provides important guidance for recruiting volunteers into future clinical trials. Furthermore, our data confirms that vaccine delivery by SLP induces humoral as well as cellular immune responses and could be considered for inclusion in future vaccine regimens where this is required.

Original languageEnglish (US)
Pages (from-to)82-93
Number of pages12
JournalImmunity Inflammation and Disease
Volume3
Issue number2
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Macaca mulatta
Vaccines
Peptides
HIV-1
Simian Adenoviruses
Vaccinia virus
vif Gene Products
gag-pol Fusion Proteins
Plasmids
Semliki forest virus
env Gene Products
T-Lymphocytes
Human Adenoviruses
HIV Antibodies
Replicon
Synthetic Vaccines
Antibodies
DNA
Macaca
Humoral Immunity

Keywords

  • Antibodies
  • Conserved regions
  • HIV vaccines
  • Macaques
  • Synthetic long peptides

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Borthwick, N. J., Rosario, M., Schiffner, T., Bowles, E., Ahmed, T., Liljeström, P., ... Hanke, T. (2015). Humoral responses to hivconsv induced by heterologous vaccine modalities in rhesus macaques. Immunity Inflammation and Disease, 3(2), 82-93. https://doi.org/10.1002/iid3.52

Humoral responses to hivconsv induced by heterologous vaccine modalities in rhesus macaques. / Borthwick, Nicola J.; Rosario, Maxim; Schiffner, Torben; Bowles, Emma; Ahmed, Tina; Liljeström, Peter; Stewart-Jones, Guillaume E.; Drijfhout, Jan W.; Melief, Cornelis J.M.; Hanke, Tomas.

In: Immunity Inflammation and Disease, Vol. 3, No. 2, 01.01.2015, p. 82-93.

Research output: Contribution to journalArticle

Borthwick, NJ, Rosario, M, Schiffner, T, Bowles, E, Ahmed, T, Liljeström, P, Stewart-Jones, GE, Drijfhout, JW, Melief, CJM & Hanke, T 2015, 'Humoral responses to hivconsv induced by heterologous vaccine modalities in rhesus macaques', Immunity Inflammation and Disease, vol. 3, no. 2, pp. 82-93. https://doi.org/10.1002/iid3.52
Borthwick, Nicola J. ; Rosario, Maxim ; Schiffner, Torben ; Bowles, Emma ; Ahmed, Tina ; Liljeström, Peter ; Stewart-Jones, Guillaume E. ; Drijfhout, Jan W. ; Melief, Cornelis J.M. ; Hanke, Tomas. / Humoral responses to hivconsv induced by heterologous vaccine modalities in rhesus macaques. In: Immunity Inflammation and Disease. 2015 ; Vol. 3, No. 2. pp. 82-93.
@article{2c18b7efb66740d68e6b6f4acf6b6698,
title = "Humoral responses to hivconsv induced by heterologous vaccine modalities in rhesus macaques",
abstract = "Vaccines delivering T cell immunogen HIVconsv vectored by plasmid DNA, non-replicating simian adenovirus and non-replicating modified vaccinia virus Ankara (MVA) are under clinical evaluation in phase I/IIa trials in UK, Europe, and Africa. While these vaccines aim to induce effector T cell responses specific for HIV-1, we here characterized the humoral responses induced by HIVconsv administration to macaques using six different vaccine modalities: plasmid DNA, human adenovirus serotype 5, simian adenovirus serotype 63, MVA, Semliki Forest virus replicons, and adjuvanted overlapping synthetic long peptides (SLP). We found that only the SLP formulation, but none of the genetic vaccine platforms induced antibodies recognizing linear HIVconsv epitopes, median 32/46 SLP.HIVconsv peptides. These antibodies bound to 15-mer and SLP peptides, recombinant gp120 and trimeric gp140 of HIV-1 Bal, YU2, JRFL, and UG037, but failed to react with HIV-1 Bal and IIIB virions and HIV-1 Bal-and IIIB-infected human cells, and consequently failed to induce neutralizing antibodies. The HIVconsv immunogen contains conserved regions derived from Gag, Pol, Vif, and Env proteins of HIV-1, and antibodies induced by the SLP.HIVconsv vaccination resulted in positive signals in routine HIV-1 tests. Thus, only HIVconsv delivered by SLP resulted in seroconversion, an observation that provides important guidance for recruiting volunteers into future clinical trials. Furthermore, our data confirms that vaccine delivery by SLP induces humoral as well as cellular immune responses and could be considered for inclusion in future vaccine regimens where this is required.",
keywords = "Antibodies, Conserved regions, HIV vaccines, Macaques, Synthetic long peptides",
author = "Borthwick, {Nicola J.} and Maxim Rosario and Torben Schiffner and Emma Bowles and Tina Ahmed and Peter Liljestr{\"o}m and Stewart-Jones, {Guillaume E.} and Drijfhout, {Jan W.} and Melief, {Cornelis J.M.} and Tomas Hanke",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/iid3.52",
language = "English (US)",
volume = "3",
pages = "82--93",
journal = "Immunity, inflammation and disease",
issn = "2050-4527",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Humoral responses to hivconsv induced by heterologous vaccine modalities in rhesus macaques

AU - Borthwick, Nicola J.

AU - Rosario, Maxim

AU - Schiffner, Torben

AU - Bowles, Emma

AU - Ahmed, Tina

AU - Liljeström, Peter

AU - Stewart-Jones, Guillaume E.

AU - Drijfhout, Jan W.

AU - Melief, Cornelis J.M.

AU - Hanke, Tomas

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Vaccines delivering T cell immunogen HIVconsv vectored by plasmid DNA, non-replicating simian adenovirus and non-replicating modified vaccinia virus Ankara (MVA) are under clinical evaluation in phase I/IIa trials in UK, Europe, and Africa. While these vaccines aim to induce effector T cell responses specific for HIV-1, we here characterized the humoral responses induced by HIVconsv administration to macaques using six different vaccine modalities: plasmid DNA, human adenovirus serotype 5, simian adenovirus serotype 63, MVA, Semliki Forest virus replicons, and adjuvanted overlapping synthetic long peptides (SLP). We found that only the SLP formulation, but none of the genetic vaccine platforms induced antibodies recognizing linear HIVconsv epitopes, median 32/46 SLP.HIVconsv peptides. These antibodies bound to 15-mer and SLP peptides, recombinant gp120 and trimeric gp140 of HIV-1 Bal, YU2, JRFL, and UG037, but failed to react with HIV-1 Bal and IIIB virions and HIV-1 Bal-and IIIB-infected human cells, and consequently failed to induce neutralizing antibodies. The HIVconsv immunogen contains conserved regions derived from Gag, Pol, Vif, and Env proteins of HIV-1, and antibodies induced by the SLP.HIVconsv vaccination resulted in positive signals in routine HIV-1 tests. Thus, only HIVconsv delivered by SLP resulted in seroconversion, an observation that provides important guidance for recruiting volunteers into future clinical trials. Furthermore, our data confirms that vaccine delivery by SLP induces humoral as well as cellular immune responses and could be considered for inclusion in future vaccine regimens where this is required.

AB - Vaccines delivering T cell immunogen HIVconsv vectored by plasmid DNA, non-replicating simian adenovirus and non-replicating modified vaccinia virus Ankara (MVA) are under clinical evaluation in phase I/IIa trials in UK, Europe, and Africa. While these vaccines aim to induce effector T cell responses specific for HIV-1, we here characterized the humoral responses induced by HIVconsv administration to macaques using six different vaccine modalities: plasmid DNA, human adenovirus serotype 5, simian adenovirus serotype 63, MVA, Semliki Forest virus replicons, and adjuvanted overlapping synthetic long peptides (SLP). We found that only the SLP formulation, but none of the genetic vaccine platforms induced antibodies recognizing linear HIVconsv epitopes, median 32/46 SLP.HIVconsv peptides. These antibodies bound to 15-mer and SLP peptides, recombinant gp120 and trimeric gp140 of HIV-1 Bal, YU2, JRFL, and UG037, but failed to react with HIV-1 Bal and IIIB virions and HIV-1 Bal-and IIIB-infected human cells, and consequently failed to induce neutralizing antibodies. The HIVconsv immunogen contains conserved regions derived from Gag, Pol, Vif, and Env proteins of HIV-1, and antibodies induced by the SLP.HIVconsv vaccination resulted in positive signals in routine HIV-1 tests. Thus, only HIVconsv delivered by SLP resulted in seroconversion, an observation that provides important guidance for recruiting volunteers into future clinical trials. Furthermore, our data confirms that vaccine delivery by SLP induces humoral as well as cellular immune responses and could be considered for inclusion in future vaccine regimens where this is required.

KW - Antibodies

KW - Conserved regions

KW - HIV vaccines

KW - Macaques

KW - Synthetic long peptides

UR - http://www.scopus.com/inward/record.url?scp=84963947646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963947646&partnerID=8YFLogxK

U2 - 10.1002/iid3.52

DO - 10.1002/iid3.52

M3 - Article

AN - SCOPUS:84963947646

VL - 3

SP - 82

EP - 93

JO - Immunity, inflammation and disease

JF - Immunity, inflammation and disease

SN - 2050-4527

IS - 2

ER -